Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention

Recruiting N/A Interventional Study
Atrial Fibrillation Coronary Artery Disease Anticoagulants
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
1,270 (estimated)
Sponsor
Zuyderland Medisch Centrum · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

A prospective, multicenter, 1:1 randomized, investigator initiated study. Goal of this study is to examine the safety of uninterrupted periprocedural DOAC use.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients aged \>18 years using DOAC and undergoing elective ICA or PCI. * Provided signed informed consent Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: Any of the following: * Patients in…
Contacts

Sanne Janssen, MSC

08854597522

sanne.janssen@zuyderland.nl

CONTACT